Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Setogepram. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 known ✓ | Q9NQS5 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.69 |
| ▸ | HPGD | P15428 | 1/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.61 |
| ▸ | PPARA | Q07869 | 4/20 | 0.60 |
| ▸ | PPARG | P37231 | 2/20 | 0.60 |
| ▸ | LPL | P06858 | 2/20 | 0.54 |
| ▸ | LIPG | Q9Y5X9 | 2/20 | 0.54 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.52 |
| ▸ | KAT8 | Q9H7Z6 | 2/20 | 0.50 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Setogepram SCHEMBL289216 | 1.00 | ALDH1A1 (0.69) | ALDH1A1HPGDHSD17B10PPARAPPARG | |
| SCHEMBL28899619 | 0.98 | ALDH1A1 (0.67) | ALDH1A1HPGDHSD17B10PPARAPPARG | |
| SCHEMBL15199282 | 0.98 | ALDH1A1 (0.67) | ALDH1A1HPGDHSD17B10PPARAPPARG | |
| Setogepram SCHEMBL19095289 | 0.98 | ALDH1A1 (0.67) | ALDH1A1HPGDHSD17B10PPARAPPARG | |
| Setogepram SCHEMBL19095287 | 0.98 | ALDH1A1 (0.67) | ALDH1A1HPGDHSD17B10PPARAPPARG | |
| SCHEMBL10963130 | 0.95 | ALDH1A1 (0.68) | ALDH1A1HPGDHSD17B10PPARAPPARG | |
| SCHEMBL15042342 | 0.87 | AKR1B1 (0.54) | ALDH1A1HPGDHSD17B10PPARAPPARG | |
| Setogepram SCHEMBL28166702 | 0.87 | ALDH1A1 (0.57) | ALDH1A1HPGDHSD17B10PPARAPPARG | |
| SCHEMBL2617117 | 0.86 | GPR84 (0.54) | ALDH1A1PPARAPPARGGPR84LPL | |
| SCHEMBL288982 | 0.86 | PPARA (0.60) | ALDH1A1PPARAPPARGLPLLIPG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 496 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4051659-B1 | SOLID STATE FORMS OF FEZAGEPRAS AND PROCESS FOR PREPARATION THEREOF | ASSIA CHEM IND LTD (IL) | 2026-01-28 | — | — | EP | claimed |
| EP-3595649-B1 | 5-((2R,4AR,10BR)-9-ETHOXY-2-HYDROXY-8-METHOXY-1,2,3,4,4A,10B-HEXAHYDRO-PHENANTHRIDIN-6-YL)1-METHYL-1H-PYRIDIN-2-ONE FOR USE IN THE TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS | TAKEDA PHARMACEUTICALS CO (JP) | 2025-10-01 | — | — | EP | claimed |
| CN-119950730-A | GPR84 receptor antagonists and resveratrol compositions and use thereof for treating migraine | 苏州健雄职业技术学院 | 2025-05-09 | — | — | CN | claimed |
| EP-4486328-A1 | TREATMENT OF SYSTEMIC SCLEROSIS AND IDIOPATHIC PULMONARY FIBROSIS | Horizon Therapeutics Ireland DAC (IE) | 2025-01-08 | — | — | EP | claimed |
| US-11939349-B2 | Galactoside inhibitor of galectins | GALECTO BIOTECH AB (DK) | 2024-03-26 | — | — | US | claimed |
| US-20230414547-A1 | METHODS OF TREATING SYSTEMIC SCLEROSIS AND IDIOPATHIC PULMONARY FIBROSIS | HORIZON THERAPEUTICS IRELAND DAC (IE) | 2023-12-28 | — | — | US | claimed |
| US-20230372434-A1 | METHOD OF TREATING FIBROSIS WITH A COMBINATION THERAPY | COHBAR, INC. | 2023-11-23 | — | — | US | claimed |
| US-11793797-B2 | Uses of a lysyl oxidase-like 2 inhibitor | PHARMAKEA, INC. (US) | 2023-10-24 | — | — | US | claimed |
| CN-116745289-A | Agonists of free fatty acid receptor 1 and their use in diseases associated with said receptor | 奥洛治疗有限公司 | 2023-09-12 | — | — | CN | claimed |
| WO-2023166348-A1 | TREATMENT OF SYSTEMIC SCLEROSIS AND IDIOPATHIC PULMONARY FIBROSIS | HORIZON THERAPEUTICS IRELAND DAC (IE) | 2023-09-07 | — | — | WO | claimed |
| US-11690839-B2 | Treatment of idiopathic pulmonary fibrosis | TAKEDA GMBH (DE) | 2023-07-04 | — | — | US | claimed |
| CN-110536682-B | Combinations of eprinox or a derivative thereof with anti-NASH, anti-fibrosis or anti-cholestasis agents | 基恩菲特公司 | 2023-01-06 | — | — | CN | claimed |
| US-20220380288-A1 | SOLID STATE FORMS OF FEZAGEPRAS AND PROCESS FOR PREPARATION THEREOF | ASSIA CHEMICAL INDUSTRIES LTD. (IL) | 2022-12-01 | — | — | US | claimed |
| US-20220380401-A1 | NOVEL GALACTOSIDE INHIBITOR OF GALECTINS | GALECTO BIOTECH AB (DK) | 2022-12-01 | — | — | US | claimed |
| US-11478440-B2 | Combination of Elafibranor or derivatives thereof with an anti-NASH, anti-fibrotic or anti-cholestatic agent | GENFIT (FR) | 2022-10-25 | — | — | US | claimed |
| EP-4073058-A1 | SOLID STATE FORM OF LEMBOREXANT | Teva Czech Industries s.r.o. (CZ) | 2022-10-19 | — | — | EP | claimed |
| EP-4051659-A1 | SOLID STATE FORMS OF FEZAGEPRAS AND PROCESS FOR PREPARATION THEREOF | Teva Pharmaceuticals International GmbH (CH) | 2022-09-07 | — | — | EP | claimed |
| WO-2022083853-A1 | AGONISTS OF FREE FATTY ACID RECEPTOR 1 AND THEIR USE IN DISEASES ASSOCIATED WITH SAID RECEPTOR | GBIOTECH S.À.R.L. (CH) | 2022-04-28 | — | — | WO | claimed |
| WO-2022087224-A1 | METHOD OF TREATING FIBROSIS WITH A COMBINATION THERAPY | COHBAR, INC. (US) | 2022-04-28 | — | — | WO | claimed |
| WO-2022073115-A1 | SUBSTITUTED AROMATIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF | BIOPHARMACEUTIQUES INGENEW INC. (CA) | 2022-04-14 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11793797-B2 | Uses of a lysyl oxidase-like 2 inhibitor | LOXL2, LOXL1, LOX | GPR84 3509/4885ALDH1A1 1140/4885HPGD 619/4885 |
| US-11478440-B2 | Combination of Elafibranor or derivatives thereof with an anti-NASH, anti-fibrotic or anti-cholestatic agent | FABP1, HDGF, HGF | GPR84 800/4885ALDH1A1 521/4885HPGD 993/4885 |
| US-20230414547-A1 | METHODS OF TREATING SYSTEMIC SCLEROSIS AND IDIOPATHIC PULMONARY FIBROSIS | LPAR2, LPAR1, LPAR3 | GPR84 478/4885ALDH1A1 907/4885HPGD 1824/4885 |
| US-20230372434-A1 | METHOD OF TREATING FIBROSIS WITH A COMBINATION THERAPY | MMP1, MMP8, COL2A1 | GPR84 3198/4885ALDH1A1 1573/4885HPGD 1108/4885 |
| US-20220380401-A1 | NOVEL GALACTOSIDE INHIBITOR OF GALECTINS | LGALS1, LGALS3, LGALS2 | GPR84 1947/4885ALDH1A1 1524/4885HPGD 3469/4885 |
| US-20220380288-A1 | SOLID STATE FORMS OF FEZAGEPRAS AND PROCESS FOR PREPARATION THEREOF | CYP2C19, CYP4A11, CYP4F11 | GPR84 1929/4885ALDH1A1 1935/4885HPGD 553/4885 |
| US-11939349-B2 | Galactoside inhibitor of galectins | LGALS1, LGALS3, LGALS2 | GPR84 1965/4885ALDH1A1 1267/4885HPGD 2964/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.